Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Flexner

Showing results (51-60 of 137) with videos related to

Pageof 14
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administrationJian-Feng Lu, Terrence F Blaschke, Charles Flexner, et al.
Antiviral Therapy|April 14, 2010
Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteersLawrence S Lee, Gaik H Soon, Ping Shen, et al.
Pharmaceutics|January 25, 2025
Investigations of Long-Acting Formulations in Children, Adolescents, and Pregnant Women: A Systematic ReviewLynn Bertagnolli, Zhengyi Deng, Melissa Davy-Rothwell, et al.
The Lancet. Infectious Diseases|June 30, 2012
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statementKeith W Crawford, David H Brown Ripin, Andrew D Levin, et al.
The Journal of Infectious Diseases|December 20, 2018
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic ModelingRajith K R Rajoli, Paul Curley, Justin Chiong, et al.
Journal of Clinical Pharmacology|March 6, 2008
Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefoliusLawrence S Lee, Stephen D Wise, Clark Chan, et al.
HIV Clinical Trials|August 21, 2002
Selected topics from the 9th Conference on Retroviruses and Opportunistic InfectionsRichard E Chaisson, Kelly Gebo, Charles Flexner, et al.
AIDS Research and Human Retroviruses|December 7, 2006
Drug development strategies for salvage therapy: conflicts and solutionsVictor De Gruttola, Charles Flexner, Jonathan Schapiro, et al.
Antimicrobial Agents and Chemotherapy|September 4, 2008
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrationsKelly Dooley, Charles Flexner, Judith Hackman, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|September 17, 2019
Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPKRajith K R Rajoli, Charles Flexner, Justin Chiong, et al.
Pageof 14

Showing results (51-60 of 137) with videos related to

Sort By:
Pageof 14
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administrationJian-Feng Lu, Terrence F Blaschke, Charles Flexner, et al.
Antiviral Therapy|April 14, 2010
Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteersLawrence S Lee, Gaik H Soon, Ping Shen, et al.
Pharmaceutics|January 25, 2025
Investigations of Long-Acting Formulations in Children, Adolescents, and Pregnant Women: A Systematic ReviewLynn Bertagnolli, Zhengyi Deng, Melissa Davy-Rothwell, et al.
The Lancet. Infectious Diseases|June 30, 2012
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statementKeith W Crawford, David H Brown Ripin, Andrew D Levin, et al.
The Journal of Infectious Diseases|December 20, 2018
Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic ModelingRajith K R Rajoli, Paul Curley, Justin Chiong, et al.
Journal of Clinical Pharmacology|March 6, 2008
Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefoliusLawrence S Lee, Stephen D Wise, Clark Chan, et al.
HIV Clinical Trials|August 21, 2002
Selected topics from the 9th Conference on Retroviruses and Opportunistic InfectionsRichard E Chaisson, Kelly Gebo, Charles Flexner, et al.
AIDS Research and Human Retroviruses|December 7, 2006
Drug development strategies for salvage therapy: conflicts and solutionsVictor De Gruttola, Charles Flexner, Jonathan Schapiro, et al.
Antimicrobial Agents and Chemotherapy|September 4, 2008
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrationsKelly Dooley, Charles Flexner, Judith Hackman, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|September 17, 2019
Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPKRajith K R Rajoli, Charles Flexner, Justin Chiong, et al.
Pageof 14